Live Chat ×
Skip to main content

Endogenous Biomarkers for OATP Inhibition

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Yurong Lai, Ph.D., Bristol-Myers Squibb Company

    Dr. Lai is a Sr. Principal Scientist at Bristol-Myers Squibb (BMS) Pharmaceutical Candidate Optimization Department. His current role in BMS is to lead the transporter labs for the implementation of drug transporter strategies in drug discovery and development and in vitro/in vivo transporter investigations for regulatory filings. Dr. Lai holds an Adjunct faculty position in the Department of Pharmacy of the University of Rhode Island. He received his M.D from Fujian Medical University in China and his Ph.D. (Toxicology) from Sapporo Medical University in Japan in 1998. From 1998 to 2001, he was a research fellow of Japanese Society for Promotion (JSPS) in Department of Physiopathology, Graduate School of Medicine of Hokkaido University, followed by a position as a Research Associate in Department of Pharmaceutics, University of Washington. In 2004, he Joined PDM, PGRD St. Louis and then moved to Groton R&D center, Pfizer Inc. in 2010. He has been serving as a PDM representative (PI), postdoc supervisor and lab head for drug transporter researches. In 2013, he joined BMS. He has had a significant role in translational researches in transporter associated ADME-PK-Tox and trained 3 postdoc fellows. Current research interests include proteomics analysis for absolute differences of transporters across species, structure-activity relationship and the evaluation of in vitro/in vivo models to predict human PK and toxicity. He is a patent inventor and the author of a book, book chapters and over 120 original publications in peer-reviewed journals.

October 20, 2016
Thu 12:30 PM EDT

Duration 1H 30M

This live web event has ended.